TEMSO phase III study results for relapsing MS

Aubagio is an oral treatment approved for MS.

TEMSO phase III study results for relapsing MS

Postby MSUK » Fri Oct 15, 2010 3:34 am

Image

Sanofi-aventis announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS).

In this study, both doses of teriflunomide (7 and 14mg) significantly reduced annualized relapse rate (primary study endpoint) by 31% vs. placebo (p is less than or equal to 0.0005). The risk of disability progression (sustained for 12 weeks) was also significantly reduced by 30% for the 14mg dose... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2933
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2180
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to Aubagio (teriflunomide)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service